Indaptus Therapeutics, Inc. (INDP) stock
INDPNasdaqPharmaceutical PreparationsFiscal year ends December 31
$3.32−0.13 (-3.77%)
Close on Nov 17, 2026Market cap $442.37MP/E –Yield –
Indaptus Therapeutics operating cash flow
Operating cash flow is the cash the business generates from its day-to-day operations.
Indaptus Therapeutics's operating cash flow for the twelve months ending Jun 30, 2026 was -$14.70M. For fiscal 2025 it was -$14.82M. The highest annual figure on record is -$3.32M in fiscal 2020.
Annual operating cash flow
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$14.82M | – |
| FY2024 | Dec 31, 2024 | -$12.32M | – |
| FY2023 | Dec 31, 2023 | -$13.41M | – |
| FY2022 | Dec 31, 2022 | -$13.08M | – |
| FY2021 | Dec 31, 2021 | -$11.29M | – |
| FY2020 | Dec 31, 2020 | -$3.32M | – |
Quarterly operating cash flow
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$1.93M | – |
| Q1 FY2026 | Mar 31, 2026 | -$7.01M | – |
| Q4 FY2025 | Dec 31, 2025 | -$3.19M | – |
| Q3 FY2025 | Sep 30, 2025 | -$2.57M | – |
| Q2 FY2025 | Jun 30, 2025 | -$4.02M | – |
| Q1 FY2025 | Mar 31, 2025 | -$5.05M | – |
| Q4 FY2024 | Dec 31, 2024 | -$3.40M | – |
| Q3 FY2024 | Sep 30, 2024 | -$2.51M | – |
| Q2 FY2024 | Jun 30, 2024 | -$2.48M | – |
| Q1 FY2024 | Mar 31, 2024 | -$3.94M | – |
| Q4 FY2023 | Dec 31, 2023 | -$2.60M | – |
| Q3 FY2023 | Sep 30, 2023 | -$3.73M | – |
| Q2 FY2023 | Jun 30, 2023 | -$2.11M | – |
| Q1 FY2023 | Mar 31, 2023 | -$4.96M | – |
| Q4 FY2022 | Dec 31, 2022 | -$2.21M | – |
| Q3 FY2022 | Sep 30, 2022 | -$4.60M | – |
| Q2 FY2022 | Jun 30, 2022 | -$3.15M | – |
| Q1 FY2022 | Mar 31, 2022 | -$3.12M | – |
| Q4 FY2021 | Dec 31, 2021 | -$3.54M | – |
| Q3 FY2021 | Sep 30, 2021 | -$5.63M | -226.5% |
| Q2 FY2021 | Jun 30, 2021 | -$1.29M | – |
| Q1 FY2021 | Mar 31, 2021 | -$825.58K | – |
| Q4 FY2020 | Dec 31, 2020 | -$957.03K | – |
| Q3 FY2020 | Sep 30, 2020 | $4.45M | – |
See a number that looks wrong?